HR Execs on the Move

Akoya Biosciences

www.akoyabio.com

 
As The Spatial Biology Company®, Akoya Biosciences` mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.akoyabio.com
  • 100 Campus Drive 6th Floor
    Marlborough, MA USA 01752
  • Phone: 855.896.8401

Executives

Name Title Contact Details
Johnny Ek
Chief Financial Officer Profile
Joe Driscoll
Chief Financial Officer Profile
Paul Bonomi
Director Supply Chain and Fulfillment Profile
Alexa Deasley
Instruments CMO and Procurement Manager Profile
Marilee Moy
Chief People Officer Profile

Similar Companies

PharmaTech

PharmaTech is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ethicon Endo-Surgery

Ethicon Endo-Surgery is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zucara Therapeutics

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.

Becton Dickinson and Company

Becton Dickinson & Company is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Renalytix

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.